U.S. stocks edge higher after weekly jobless claims; Salesforce gains
DUBLIN - Morgan Stanley & Co. International plc disclosed its dealings in Avadel Pharmaceuticals plc (NASDAQ:AVDL) securities in compliance with Irish Takeover Panel rules, according to a regulatory filing released Thursday.
The filing, made under Rule 38.5(a) of the Irish Takeover Panel Act, shows that Morgan Stanley, acting as an exempt principal trader with recognized intermediary status, conducted transactions in Avadel Pharmaceuticals ordinary shares on November 19, 2025.
The disclosure reveals that Morgan Stanley purchased and subsequently sold 709 ordinary shares of Avadel Pharmaceuticals. The transactions occurred at prices ranging from $23.0175 to $23.0938 per share.
Morgan Stanley confirmed in the filing that it is connected to Avadel Pharmaceuticals in relation to an unspecified offer. The company stated it has no indemnity arrangements, agreements, or understandings relating to options or derivatives regarding Avadel securities.
The disclosure was made in accordance with the requirements for exempt principal traders dealing in a client-serving capacity under Irish takeover regulations. Such disclosures are mandatory when a trader connected to a party involved in a takeover conducts transactions in relevant securities.
No cash-settled derivative transactions, stock-settled derivative transactions, or other dealings were reported in the filing.
The information was submitted to a Regulatory Information Service as required by Rule 38 of the Irish Takeover Panel rules, based on the company's press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.